HEADER TRANSCRIPTION/TRANSCRIPTION AGONIST 27-OCT-10 3PEQ TITLE PPARD COMPLEXED WITH A PHENOXYACETIC ACID PARTIAL AGONIST COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: UNP RESIDUES 171-441; COMPND 5 SYNONYM: PPAR-DELTA, NUCI, NUCLEAR HORMONE RECEPTOR 1, NUC1, NUCLEAR COMPND 6 RECEPTOR SUBFAMILY 1 GROUP C MEMBER 2, PEROXISOME PROLIFERATOR- COMPND 7 ACTIVATED RECEPTOR BETA, PPAR-BETA; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: NR1C2, PPARB, PPARD; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PRSETA KEYWDS PPAR NUCLEAR RECEPTOR, TRANSCRIPTION-TRANSCRIPTION AGONIST COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR M.H.LAMBERT,K.A.EVANS,B.G.SHEARER,D.D.WISNOSKI,D.SHI,J.JIN, AUTHOR 2 R.A.RIVERO,S.M.SPARKS,D.A.WINEGAR,A.N.BILLIN,C.BRITT,J.M.WAY, AUTHOR 3 L.M.LEESNITZER,R.V.MERRIHEW REVDAT 4 06-SEP-23 3PEQ 1 HETSYN REVDAT 3 29-JUL-20 3PEQ 1 REMARK SITE REVDAT 2 08-OCT-14 3PEQ 1 AUTHOR REVDAT 1 12-OCT-11 3PEQ 0 JRNL AUTH K.A.EVANS,B.G.SHEARER,D.D.WISNOSKI,D.SHI,S.M.SPARKS, JRNL AUTH 2 D.D.STERNBACH,D.A.WINEGAR,A.N.BILLIN,C.BRITT,J.M.WAY, JRNL AUTH 3 A.H.EPPERLY,L.M.LEESNITZER,R.V.MERRIHEW,R.X.XU,M.H.LAMBERT, JRNL AUTH 4 J.JIN JRNL TITL PHENOXYACETIC ACID PPARD PARTIAL AGONISTS FOR THE TREATMENT JRNL TITL 2 OF TYPE 2 DIABETES: SYNTHESIS, OPTIMIZATION, AND IN VIVO JRNL TITL 3 EFFICACY JRNL REF BIOORG.MED.CHEM.LETT. V. 21 2345 2011 JRNL REFN ISSN 0960-894X JRNL PMID 21414782 JRNL DOI 10.1016/J.BMCL.2011.02.077 REMARK 2 REMARK 2 RESOLUTION. 2.40 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.5.0109 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.40 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.26 REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 97.6 REMARK 3 NUMBER OF REFLECTIONS : 25794 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.201 REMARK 3 R VALUE (WORKING SET) : 0.199 REMARK 3 FREE R VALUE : 0.237 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1390 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.40 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.46 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1891 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 94.78 REMARK 3 BIN R VALUE (WORKING SET) : 0.2360 REMARK 3 BIN FREE R VALUE SET COUNT : 108 REMARK 3 BIN FREE R VALUE : 0.2860 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4064 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 136 REMARK 3 SOLVENT ATOMS : 167 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 48.36 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.69000 REMARK 3 B22 (A**2) : 2.36000 REMARK 3 B33 (A**2) : -2.89000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.58000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): 0.241 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.170 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 14.300 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.948 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.937 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 4320 ; 0.007 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 5860 ; 1.053 ; 1.995 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 517 ; 4.704 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 186 ;36.270 ;24.140 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 730 ;13.435 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 21 ;17.237 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 675 ; 0.067 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 3279 ; 0.004 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 2587 ; 0.364 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 4174 ; 0.715 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1733 ; 1.042 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 1681 ; 1.778 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 2 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 209 A 475 REMARK 3 ORIGIN FOR THE GROUP (A): 28.1660 8.1280 66.1630 REMARK 3 T TENSOR REMARK 3 T11: 0.0484 T22: 0.0241 REMARK 3 T33: 0.0511 T12: 0.0001 REMARK 3 T13: -0.0185 T23: -0.0009 REMARK 3 L TENSOR REMARK 3 L11: 2.7204 L22: 2.2629 REMARK 3 L33: 3.3815 L12: 0.3096 REMARK 3 L13: -0.7925 L23: 0.3364 REMARK 3 S TENSOR REMARK 3 S11: -0.0388 S12: 0.1493 S13: -0.1580 REMARK 3 S21: 0.0759 S22: 0.0497 S23: 0.0651 REMARK 3 S31: -0.0203 S32: -0.2326 S33: -0.0110 REMARK 3 REMARK 3 TLS GROUP : 2 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : B 209 B 477 REMARK 3 ORIGIN FOR THE GROUP (A): 0.0480 -1.6290 18.9240 REMARK 3 T TENSOR REMARK 3 T11: 0.1892 T22: 0.0342 REMARK 3 T33: 0.0451 T12: -0.0372 REMARK 3 T13: 0.0384 T23: -0.0139 REMARK 3 L TENSOR REMARK 3 L11: 2.2286 L22: 2.0580 REMARK 3 L33: 7.0576 L12: 0.5513 REMARK 3 L13: 0.0826 L23: -1.1041 REMARK 3 S TENSOR REMARK 3 S11: -0.0032 S12: 0.0847 S13: 0.1409 REMARK 3 S21: -0.0576 S22: 0.0938 S23: 0.0418 REMARK 3 S31: -0.4607 S32: 0.3365 S33: -0.0906 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS REMARK 4 REMARK 4 3PEQ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 01-NOV-10. REMARK 100 THE DEPOSITION ID IS D_1000062287. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 12-JUN-06 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 9.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : SAGITALLY FOCUSED SI REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 25794 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.400 REMARK 200 RESOLUTION RANGE LOW (A) : 30.260 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.0 REMARK 200 DATA REDUNDANCY : 3.000 REMARK 200 R MERGE (I) : 0.07500 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 17.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.40 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.46 REMARK 200 COMPLETENESS FOR SHELL (%) : 94.8 REMARK 200 DATA REDUNDANCY IN SHELL : 2.60 REMARK 200 R MERGE FOR SHELL (I) : 0.43000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: PDB ENTRY 1GWX REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 59.36 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.03 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 100 MM POTASSIUM IODIDE, 20% PEG3350, REMARK 280 PH 9.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 47.76750 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2780 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 22950 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -17.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 2 -1.000000 0.000000 0.000000 26.43720 REMARK 350 BIOMT2 2 0.000000 1.000000 0.000000 47.76750 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 95.65295 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLN A 207 REMARK 465 VAL A 208 REMARK 465 GLY A 239 REMARK 465 LYS A 240 REMARK 465 ALA A 241 REMARK 465 SER A 242 REMARK 465 HIS A 243 REMARK 465 THR A 244 REMARK 465 LYS A 265 REMARK 465 GLN A 266 REMARK 465 LEU A 267 REMARK 465 VAL A 268 REMARK 465 ASN A 269 REMARK 465 GLY A 270 REMARK 465 MET A 476 REMARK 465 TYR A 477 REMARK 465 GLN B 207 REMARK 465 VAL B 208 REMARK 465 GLY B 239 REMARK 465 LYS B 240 REMARK 465 ALA B 241 REMARK 465 SER B 242 REMARK 465 HIS B 243 REMARK 465 THR B 244 REMARK 465 LYS B 265 REMARK 465 GLN B 266 REMARK 465 LEU B 267 REMARK 465 VAL B 268 REMARK 465 ASN B 269 REMARK 465 GLY B 270 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 212 CG CD CE NZ REMARK 470 LYS A 260 CD CE NZ REMARK 470 LEU A 262 CG CD1 CD2 REMARK 470 LYS A 336 CE NZ REMARK 470 GLN A 429 CG CD OE1 NE2 REMARK 470 TYR A 430 CD1 CD2 CE1 CE2 CZ OH REMARK 470 GLU A 462 CG CD OE1 OE2 REMARK 470 ASP B 210 CG OD1 OD2 REMARK 470 LYS B 212 CG CD CE NZ REMARK 470 LYS B 216 CG CD CE NZ REMARK 470 LYS B 232 CG CD CE NZ REMARK 470 THR B 238 OG1 CG2 REMARK 470 LYS B 260 CD CE NZ REMARK 470 LEU B 262 CG CD1 CD2 REMARK 470 LYS B 336 CG CD CE NZ REMARK 470 GLN B 429 CG CD OE1 NE2 REMARK 470 TYR B 430 CG CD1 CD2 CE1 CE2 CZ OH REMARK 470 ARG B 455 CG CD NE CZ NH1 NH2 REMARK 470 LYS B 458 CG CD CE NZ REMARK 470 GLU B 462 CG CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 260 20.13 -70.24 REMARK 500 TYR A 430 51.99 39.18 REMARK 500 GLU A 460 75.97 -100.60 REMARK 500 VAL B 263 -36.55 -130.79 REMARK 500 ASP B 427 35.63 -99.76 REMARK 500 REMARK 500 REMARK: NULL DBREF 3PEQ A 207 477 UNP Q03181 PPARD_HUMAN 171 441 DBREF 3PEQ B 207 477 UNP Q03181 PPARD_HUMAN 171 441 SEQRES 1 A 271 GLN VAL ALA ASP LEU LYS ALA PHE SER LYS HIS ILE TYR SEQRES 2 A 271 ASN ALA TYR LEU LYS ASN PHE ASN MET THR LYS LYS LYS SEQRES 3 A 271 ALA ARG SER ILE LEU THR GLY LYS ALA SER HIS THR ALA SEQRES 4 A 271 PRO PHE VAL ILE HIS ASP ILE GLU THR LEU TRP GLN ALA SEQRES 5 A 271 GLU LYS GLY LEU VAL TRP LYS GLN LEU VAL ASN GLY LEU SEQRES 6 A 271 PRO PRO TYR LYS GLU ILE SER VAL HIS VAL PHE TYR ARG SEQRES 7 A 271 CYS GLN CYS THR THR VAL GLU THR VAL ARG GLU LEU THR SEQRES 8 A 271 GLU PHE ALA LYS SER ILE PRO SER PHE SER SER LEU PHE SEQRES 9 A 271 LEU ASN ASP GLN VAL THR LEU LEU LYS TYR GLY VAL HIS SEQRES 10 A 271 GLU ALA ILE PHE ALA MET LEU ALA SER ILE VAL ASN LYS SEQRES 11 A 271 ASP GLY LEU LEU VAL ALA ASN GLY SER GLY PHE VAL THR SEQRES 12 A 271 ARG GLU PHE LEU ARG SER LEU ARG LYS PRO PHE SER ASP SEQRES 13 A 271 ILE ILE GLU PRO LYS PHE GLU PHE ALA VAL LYS PHE ASN SEQRES 14 A 271 ALA LEU GLU LEU ASP ASP SER ASP LEU ALA LEU PHE ILE SEQRES 15 A 271 ALA ALA ILE ILE LEU CYS GLY ASP ARG PRO GLY LEU MET SEQRES 16 A 271 ASN VAL PRO ARG VAL GLU ALA ILE GLN ASP THR ILE LEU SEQRES 17 A 271 ARG ALA LEU GLU PHE HIS LEU GLN ALA ASN HIS PRO ASP SEQRES 18 A 271 ALA GLN TYR LEU PHE PRO LYS LEU LEU GLN LYS MET ALA SEQRES 19 A 271 ASP LEU ARG GLN LEU VAL THR GLU HIS ALA GLN MET MET SEQRES 20 A 271 GLN ARG ILE LYS LYS THR GLU THR GLU THR SER LEU HIS SEQRES 21 A 271 PRO LEU LEU GLN GLU ILE TYR LYS ASP MET TYR SEQRES 1 B 271 GLN VAL ALA ASP LEU LYS ALA PHE SER LYS HIS ILE TYR SEQRES 2 B 271 ASN ALA TYR LEU LYS ASN PHE ASN MET THR LYS LYS LYS SEQRES 3 B 271 ALA ARG SER ILE LEU THR GLY LYS ALA SER HIS THR ALA SEQRES 4 B 271 PRO PHE VAL ILE HIS ASP ILE GLU THR LEU TRP GLN ALA SEQRES 5 B 271 GLU LYS GLY LEU VAL TRP LYS GLN LEU VAL ASN GLY LEU SEQRES 6 B 271 PRO PRO TYR LYS GLU ILE SER VAL HIS VAL PHE TYR ARG SEQRES 7 B 271 CYS GLN CYS THR THR VAL GLU THR VAL ARG GLU LEU THR SEQRES 8 B 271 GLU PHE ALA LYS SER ILE PRO SER PHE SER SER LEU PHE SEQRES 9 B 271 LEU ASN ASP GLN VAL THR LEU LEU LYS TYR GLY VAL HIS SEQRES 10 B 271 GLU ALA ILE PHE ALA MET LEU ALA SER ILE VAL ASN LYS SEQRES 11 B 271 ASP GLY LEU LEU VAL ALA ASN GLY SER GLY PHE VAL THR SEQRES 12 B 271 ARG GLU PHE LEU ARG SER LEU ARG LYS PRO PHE SER ASP SEQRES 13 B 271 ILE ILE GLU PRO LYS PHE GLU PHE ALA VAL LYS PHE ASN SEQRES 14 B 271 ALA LEU GLU LEU ASP ASP SER ASP LEU ALA LEU PHE ILE SEQRES 15 B 271 ALA ALA ILE ILE LEU CYS GLY ASP ARG PRO GLY LEU MET SEQRES 16 B 271 ASN VAL PRO ARG VAL GLU ALA ILE GLN ASP THR ILE LEU SEQRES 17 B 271 ARG ALA LEU GLU PHE HIS LEU GLN ALA ASN HIS PRO ASP SEQRES 18 B 271 ALA GLN TYR LEU PHE PRO LYS LEU LEU GLN LYS MET ALA SEQRES 19 B 271 ASP LEU ARG GLN LEU VAL THR GLU HIS ALA GLN MET MET SEQRES 20 B 271 GLN ARG ILE LYS LYS THR GLU THR GLU THR SER LEU HIS SEQRES 21 B 271 PRO LEU LEU GLN GLU ILE TYR LYS ASP MET TYR HET 3EQ A 1 38 HET JZR A 478 18 HET JZR A 3 18 HET IOD A 2 1 HET IOD A 6 1 HET IOD A 7 1 HET IOD A 8 1 HET 3EQ B 2 38 HET JZR B 478 18 HET IOD B 3 1 HET IOD B 5 1 HETNAM 3EQ [(4-{BUTYL[2-METHYL-4'-(METHYLSULFANYL)BIPHENYL-3- HETNAM 2 3EQ YL]SULFAMOYL}NAPHTHALEN-1-YL)OXY]ACETIC ACID HETNAM JZR HEXYL BETA-D-GLUCOPYRANOSIDE HETNAM IOD IODIDE ION HETSYN JZR HEXYL BETA-D-GLUCOSIDE; HEXYL D-GLUCOSIDE; HEXYL HETSYN 2 JZR GLUCOSIDE FORMUL 3 3EQ 2(C30 H31 N O5 S2) FORMUL 4 JZR 3(C12 H24 O6) FORMUL 6 IOD 6(I 1-) FORMUL 14 HOH *167(H2 O) HELIX 1 1 ASP A 210 PHE A 226 1 17 HELIX 2 2 THR A 229 THR A 238 1 10 HELIX 3 3 ASP A 251 LYS A 260 1 10 HELIX 4 4 GLU A 276 SER A 302 1 27 HELIX 5 5 ILE A 303 SER A 308 1 6 HELIX 6 6 PHE A 310 ALA A 331 1 22 HELIX 7 7 ARG A 350 SER A 355 1 6 HELIX 8 8 PRO A 359 ALA A 376 1 18 HELIX 9 9 ASP A 380 LEU A 393 1 14 HELIX 10 10 ASN A 402 HIS A 425 1 24 HELIX 11 11 TYR A 430 GLU A 460 1 31 HELIX 12 12 HIS A 466 LYS A 474 1 9 HELIX 13 13 ASP B 210 PHE B 226 1 17 HELIX 14 14 THR B 229 THR B 238 1 10 HELIX 15 15 ASP B 251 LYS B 260 1 10 HELIX 16 16 GLU B 276 SER B 302 1 27 HELIX 17 17 ILE B 303 LEU B 309 1 7 HELIX 18 18 PHE B 310 ALA B 331 1 22 HELIX 19 19 ARG B 350 SER B 355 1 6 HELIX 20 20 PRO B 359 ALA B 376 1 18 HELIX 21 21 ASP B 380 LEU B 393 1 14 HELIX 22 22 ASN B 402 HIS B 425 1 24 HELIX 23 23 TYR B 430 GLU B 460 1 31 HELIX 24 24 HIS B 466 LYS B 474 1 9 SHEET 1 A 4 PHE A 247 ILE A 249 0 SHEET 2 A 4 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 A 4 GLY A 338 VAL A 341 -1 N LEU A 339 O VAL A 348 SHEET 4 A 4 VAL A 334 ASN A 335 -1 N ASN A 335 O GLY A 338 SHEET 1 B 4 PHE B 247 ILE B 249 0 SHEET 2 B 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 B 4 GLY B 338 VAL B 341 -1 N VAL B 341 O GLY B 346 SHEET 4 B 4 VAL B 334 ASN B 335 -1 N ASN B 335 O GLY B 338 CISPEP 1 LYS A 358 PRO A 359 0 5.14 CISPEP 2 LYS B 358 PRO B 359 0 1.64 CRYST1 39.472 95.535 96.537 90.00 97.76 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.025334 0.000000 0.003453 0.00000 SCALE2 0.000000 0.010467 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010454 0.00000